OR WAIT 15 SECS
RALEIGH, N.C., April 23, 2015 – INC Research Holdings, Inc. (Nasdaq: INCR), a leading, global Phase I to IV contract research organization (CRO), today announced a strategic collaboration with DrugDev to drive increased efficiencies in clinical trials through enhanced access to and management of critical investigator and site data. Under the agreement, INC Research becomes the first CRO to complete integration with and implementation of DrugDev’s SiteCloud platform, the same technology used by TransCelerate’s Investigator Registry (launching later this year) and the Investigator Databank, to facilitate more efficient feasibility, site selection and study start-up processes.
“INC Research is continuously looking to advance clinical research and patient and site engagement through innovation,” said Clare Grace, Vice President, Site and Patient Access. “DrugDev provides cutting-edge solutions that help drive the biopharmaceutical industry forward. Cloud-based offerings like SiteCloud are the latest examples of the tools and resources INC uses to share critical investigative site data with our customers and drive increased efficiencies at critical points along the drug development continuum.”
DrugDev is an innovative technology company that provides unified global solutions to help sponsors, CROs and sites do more trials together. Using a universal identifier known as the DrugDev Golden Number, the SiteCloud platform matches and masters data from numerous disparate sources (such as INC’s internal experience, the DrugDev Network of 80,000 opted-in global investigators across 115 countries and trusted third-party resources) to create a virtual private database (VPD) for INC with precise site and investigator profiles that will be used to make superior evidence-based decisions.
SiteCloud enables INC Research to make evidence-driven site selection decisions, while the DrugDev Golden Number enables INC to collaborate and integrate more efficiently with pharmaceutical customers also using the DrugDev platform. The adoption of this innovative technology further demonstrates INC’s commitment to finding the right sites for every clinical trial, which in turn improves the clinical research process for global sites and sponsors alike.
As part of the strategic collaboration, INC will continue to work with DrugDev on implementation of additional innovative technologies that improve clinical development and bring new medicines to patients faster. “INC’s collaboration with DrugDev is another example of our commitment to industry innovation that will drive significant improvement in how CROs deliver greater quality at higher velocity,” added Jonathan Shough, Chief Information Officer.
“Real change will only come to the clinical research industry through meaningful collaboration and the widespread adoption of technology standards such as the DrugDev Golden Number, so naturally we could not be more excited to work with INC Research on this essential initiative,” said Ibraheem (Ibs) Mahmood, President and CEO of DrugDev. “As a platform-agnostic leader, INC is committed to leveraging future-proof technologies that best meet customer requirements, and we are honored that they have chosen SiteCloud as their preferred platform for site and investigator data sharing and management.”